CUE News and Press, Cue Biopharma Inc. From 05/09/23

2023-05-09 18:01:56 ET Cue Biopharma press release ( NASDAQ: CUE ): Q1 GAAP EPS of -$0.29 in-line. Revenue of $0.19M (-81.0% Y/Y) misses by $1.76M . For further details see: Cue Biopharma GAAP EPS of -$0.29 in-line, revenue of $0.19M misses by $1.76M

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, provided a business an...

2023-05-04 13:56:05 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Most of the biggest biotech stocks on the market started off as unknown penny stocks . Look at Axsome Therapeutics (NASDAQ: AXSM ), for example. At one time, it was a $2.50 ...

BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today the ...

BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today the ...

2023-03-21 23:00:23 ET Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Conference Call March 21, 2023, 04:30 PM ET Company Participants Dan Passeri - CEO Matteo Levisetti - Chief Medical Officer Ken Pienta - Clinical Advisory Anish Suri - President and Chief Scien...

2023-03-21 16:28:48 ET Cue Biopharma press release ( NASDAQ: CUE ): Q4 GAAP EPS of -$0.37 misses by $0.06 . Revenue of $0.15M (-98.2% Y/Y) beats by $0.05M . Research and development expenses were $11.3 million and $11.5 million for the three...

Received U.S. Food and Drug Administration (FDA) acceptance of Investigational New Drug (IND) application for CUE-102 in Wilms’ Tumor 1 (WT1)-expressing cancers and initiated dosing in a Phase 1 dose escalation monotherapy trial at 1mg/kg. Granted FDA Fast Track Designation fo...

BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that...

BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today a col...